Table 3.

Patient clinical characteristics

Patient ID no.Infused VSTsHLA matchingViral diseaseReduction in immuno-suppressionPrior antiviral(s)Duration prior antiviral therapyAntiviral drug intoleranceCMV resistanceChange in antiviral post-VSTResponse by 6 wkOverall outcome
3910C67902/8NoNoGanciclovir17NoNoNoCRSustained CR
3944C67984/8NoNoLeflunomide94AKI, cytopeniaYesNoCRSustained CR
3976C67986/8NoYes, reduction in tacrolimus between wk 4 and 6Foscarnet, ganciclovir14Renal tubulopathyYes (U97 mutation)NoCRSustained CR after second infusion
3762C68085/8CMV retinitisNoNoneUnable to toleratePoor graft functionNot doneYes, ganciclovir administered for 1 wkCRSustained CR
3967C68232/8CMV colitis (diarrhea)NoFoscarnet211AKIYes (U97 mutation)NoPRDied of renal failure and AdV infection
4091C67905/8NoNoFoscarnet, cidofovir, leflunomide29AKINot doneNoCRDied of renal failure
4115C68345/8NoNoFoscarnet24AKINot doneNoCRSustained CR
4170C67903/8NoNoGanciclovir, foscarnet42PancreatitisNoNoCRSustained CR
4134C67985/8CMV colitis (diarrhea)NoFoscarnet, ganciclovir17NoNot doneNoPRSustained CR
4201C68143/8NoYes, tacrolimus taper initiated before VST infusionFoscarnet, ganciclovir41NoNoNoPRSustained CR after third infusion
  • AdV, adenovirus; AKI, acute kidney injury; PR, partial response.